ArticleNeural plasticity2025
Transient Receptor Potential Vanilloid 4 Antagonist Eliminated Age-Related Spatial Memory Deficit in Female Sprague Dawley Rats.
Article in Neural plasticity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The expression of transient receptor potential vanilloid 4 (TRPV4) channels in the brains of normal-aging individuals significantly increases. However, the involvement of TRPV4 activity in age-related memory impairment remains unknown. This study aimed to investigate the role of TRPV4 in spatial memory tasks, hippocampal inflammation, and hippocampal autophagy in adolescent, adult, and aged female rats. Rats of different ages were used: 5, 10, 19, and 19 months treated with a TRPV4 inhibitor. Memory performance was assessed using the Morris water maze (MWM). Molecular changes were evaluated through western blotting, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). The hippocampal TRPV4 expression was significantly increased in the aged rats. Furthermore, aged rats exhibited spatial memory decline, which was normalized with TRPV4 antagonist GSK2193874 (GSK219) injection. The senescence-associated β-galactosidase (SA-β-Gal) activity and hippocampal inflammatory cytokine and microglial activation marker levels in the hippocampus of aged rats were significantly increased. Similarly, the phosphoprotein marker levels of autophagy in the hippocampus of aged rats were significantly increased. GSK219 treatment effectively normalized hippocampal SA-β-Gal activity, inflammation, and autophagy in aged rats. TRPV4 hyperactivity was found to induce hippocampal inflammation and neuronal death, leading to spatial memory impairment in normal aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.